Phase 1 Thorough QT (TQT) Study in Young Healthy Volunteers

• Drug: esreboxetine
  
  Once daily administration of 4mg esreboxetine for 3 days, followed by 8mg esreboxetine for 3 days, followed by 10mg esreboxetine for 3 days. Drug will be administered double-blind.
• Drug: placebo
  
  Once daily administration of placebo for 9 days. Placebo will be administered double blind
• Drug: moxifloxacin
  
  Once daily administration of placebo for 8 days followed by open label single oral dose of 400mg moxifloxacin on day 9

• Experimental: One
  
  Intervention: Drug: esreboxetine
• Placebo Comparator: Two
  
  Intervention: Drug: placebo
• Active Comparator: Three
  
  Administration of a single oral dse of 400mg moxifloxacin
  Intervention: Drug: moxifloxacin

Inclusion Criteria:

• Healthy male and female subjects aged 18 to 55 years
• Body mass Index of approximately 18 to 30kg/m2
• Informed consent document signed by the subject or a legally acceptable representative
• Subjects who are willing and able to comply with the scheduled visits, treatment tests, laboratory tests, and other study procedures

Exclusion Criteria:

• Evidence or history of clinically significant haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic psychiatric, neurologic or allergic disease or clinical findings at screening
• Conditions possibly affecting drug absorption
• 12-lead ECg demonstrating QTc > 450ms or any other clinically significant abnormalities at screen
• Positive urine drug screen
• Hypersensitivity to moxifloxacin
• Unwilling or unable to comply with the lifestyle guidelines in the protocol Treatment with an investigational drug within 3 months or 5 half lives (whichever is longer) preceding the first dose of study medication